Article
A 'breakthrough' PD-1? From China? FDA says why not for rare cancer
Rating:
0.0
Views:
186
Likes:
1
Library:
1
PD-(L)1 inhibitors may be the standard of care and the cornerstone therapy for a number of cancers, but in other niches, the FDA is still happy to consider them a breakthrough. Late Thursday — and early Friday in China — regulators granted the breakthrough designation to Junshi Biosciences. It's a
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value